Stock Price & Analysis

Based on the recent market data and analyst insights, here is a concise analysis of MDT stock:

Technical Analysis

• MDT is showing a downward trend in the short term, with the stock closing at $83.56 on February 23rd, down from recent highs around $86 in early February
• The stock has been trading in a range between $81-86 over the past month, suggesting consolidation

Fundamental Factors

• Q3 FY2025 earnings are expected to show EPS of $1.36, representing 4.6% growth year-over-year
• The company has consistently beat earnings estimates in the last four quarters
• Recent supplier issues in the cardiac ablation unit have impacted sales performance

Analyst Consensus

• Among 28 analysts covering MDT:
  • 10 Strong Buy
  • 1 Moderate Buy
  • 15 Hold
  • 2 Strong Sell
• Mean price target of $93.83, suggesting 12.3% upside potential from current levels

Based on the technical weakness and mixed analyst sentiment, despite solid fundamentals, investors should HOLD MDT stock at current levels. The stock appears fairly valued with limited near-term catalysts, though long-term prospects remain positive given the company's market leadership in medical devices.

Based on the provided data and recent market developments, here's the price prediction for MDT stock in 2025:

Medtronic (MDT) is expected to reach $97-98 by end of 2025, representing an 8-9% upside from current price of $89.91, driven by improving operational efficiency and continued dividend growth. The company's recent Q3 FY2025 results showed steady performance with adjusted EPS of $1.39 beating estimates, while management reiterated full-year organic revenue growth guidance of 4.75-5%.

The technical analysis shows MDT trading above both 60-day ($85.83) and 200-day ($84.73) moving averages, with Fibonacci resistance levels at $92.40 and $94.29 providing near-term targets. The RSI at 53.37 indicates balanced momentum without being overbought.

The S1 support level for MDT Stock is $86.29 ,The R1 resistant level for MDT Stock is $92.39.

As of the end of day on 2025-02-26, the price of MDT Stock was $90.79.

The target price for MDT Stock according to analyst rating is 95.64, with the highest price target at 109.00 and the lowest at 85.00. Analysts have a Moderate Buy rating on MDT Stock overall.

The market cap of MDT is $116.1B.

Based on the provided data and recent market developments, I'll analyze whether MDT is overvalued:

Technical Analysis

Valuation Metrics

• Current P/E (FY2023): 32.26x, higher than historical average of 27.99x
• EV/EBITDA: 14.97x, showing slight improvement from 15.78x
• P/S: 3.88x, decreased from 4.45x
• P/B: 2.35x, lower than previous 2.64x

Recent Performance & Fundamentals

• Revenue declined by 1.45% YoY (FY2023: $31.23B vs FY2022: $31.69B)
• Net income dropped by 25.4% (FY2023: $3.76B vs FY2022: $5.04B)
• Gross margin deteriorated to 60.55% from 63.06%
• ROE declined to 7.22% from 9.69%

Latest Developments

• Q3 FY2025 results showed revenue miss at $8.3B vs expected $8.33B
• However, adjusted EPS of $1.39 beat estimates of $1.35
• Management maintains FY2025 organic revenue growth guidance of 4.75-5%
• Current dividend yield of 3.24% with 47 consecutive years of increases

Conclusion MDT is not overvalued when considering:

1. Trading below historical valuation multiples
2. Showing operational improvements despite recent challenges
3. Maintaining stable growth guidance
4. Strong dividend history and yield
5. Current technical indicators showing neutral to slightly bullish momentum

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.

Based on the provided data and market analysis, here is the price prediction for MDT stock by 2030:

Medtronic (MDT) stock is projected to reach $135-140 by 2030, driven by its strong position in medical devices market and consistent dividend growth track record. The company's focus on high-growth markets and restored earnings power, with projected FY2025 organic revenue growth of 4.75-5%, supports this long-term target. Recent technical indicators and fibonacci levels suggest a stable upward trajectory, with key resistance at $94.29 acting as near-term ceiling.

MDT has a total of 95000 employees.